Epidermal growth factor receptors (EGFR) are overexpressed in pancreatic cancers; however, PDAC is resistant to anti‐EGFR monotherapies and combination therapies.66, 67 Abolishment of EGFR transduction is compensated by integrin β‐1‐driven Src‐Akt signaling that promotes cell survival. This evidence concerns the gene EGFR and familial pancreatic carcinoma.